MiNK Therapeutics, Inc. (INKT) Financial Statements (2024 and earlier)

Company Profile

Business Address 149 FIFTH AVENUE
NEW YORK, NY 10010
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2023
MRQ
12/31/2022
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments19,635,72538,888,828
Cash and cash equivalents19,635,72538,888,828
Receivables  23,000
Prepaid expense298,6671,761
Other current assets470,300744,321
Other undisclosed current assets  (23,000)
Total current assets:20,404,69239,634,910
Noncurrent Assets
Property, plant and equipment1,066,910606,595
Total noncurrent assets:1,066,910606,595
TOTAL ASSETS:21,471,60240,241,505
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities10,061,5554,759,333
Accounts payable5,823,0002,995,645
Accrued liabilities4,238,5551,763,688
Due to related parties 5,945,094
Other liabilities2,621,6115,760,609
Total current liabilities:12,683,16616,465,036
Noncurrent Liabilities
Liabilities, other than long-term debt9,189,739 
Due to related parties9,081,239 
Other liabilities108,500 
Total noncurrent liabilities:9,189,739 
Total liabilities:21,872,90516,465,036
Equity
Equity, attributable to parent(401,303)23,776,469
Common stock339335
Additional paid in capital110,829,900107,349,265
Accumulated other comprehensive loss(292,468)(625,269)
Accumulated deficit(110,939,074)(82,947,862)
Total equity:(401,303)23,776,469
Other undisclosed liabilities and equity  
TOTAL LIABILITIES AND EQUITY:21,471,60240,241,505

Income Statement (P&L) (USD)

9/30/2023
TTM
12/31/2022
12/31/2021
Operating expenses(30,949,278)(18,606,296)
Other undisclosed operating loss  (9,752,295)
Operating loss:(30,949,278)(28,358,591)
Nonoperating income (expense)2,690,743(185,080)
Loss, foreign currency transaction, before tax (14,000)(407,000)
Other nonoperating income2,704,743221,920
Interest and debt expense  (2,076,099)
Loss from continuing operations:(28,258,535)(30,619,770)
Loss before gain (loss) on sale of properties:(30,619,770)
Other undisclosed net income267,323407,000
Net loss:(27,991,212)(30,212,770)
Other undisclosed net income attributable to parent  
Net loss available to common stockholders, diluted:(27,991,212)(30,212,770)

Comprehensive Income (USD)

9/30/2023
TTM
12/31/2022
12/31/2021
Net loss:(27,991,212)(30,212,770)
Other comprehensive income (loss)332,801897,769
Other undisclosed comprehensive income  
Comprehensive loss:(27,658,411)(29,315,001)
Other undisclosed comprehensive loss, net of tax, attributable to parent  
Comprehensive loss, net of tax, attributable to parent:(27,658,411)(29,315,001)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: